Lumigan

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instance_of gptkb:sneaker
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Latisse
gptkbp:approves gptkb:FDA
gptkbp:average_temperature room temperature
gptkbp:brand gptkb:Lumigan
gptkbp:category Category C
gptkbp:class prostaglandin analogs
gptkbp:clinical_trial Phase III trials
ophthalmology
gptkbp:community_service safety not established
gptkbp:contraindication hypersensitivity to bimatoprost
gptkbp:dosage_form gptkb:software_framework
gptkbp:duration 24 hours
gptkbp:effective_date gptkb:2001
gptkbp:excretion urine
gptkbp:formulation gptkb:sneaker
newer formulations available
https://www.w3.org/2000/01/rdf-schema#label Lumigan
gptkbp:indication gptkb:ocular_hypertension
gptkbp:ingredients gptkb:bimatoprost
gptkbp:interacts_with other eye medications
systemic medications
gptkbp:is_available_on generic version
gptkbp:is_used_for treatment of glaucoma
gptkbp:manager topical
gptkbp:manufacturer gptkb:Allergan
gptkbp:marketed_as gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
gptkbp:metabolism liver
gptkbp:packaging gptkb:beer
gptkbp:population instructions for use
gptkbp:premiered_on 4 hours
gptkbp:price varies by pharmacy
gptkbp:provides_information_on gptkb:American_Academy_of_Ophthalmology
gptkb:European_Glaucoma_Society
follow prescribing information
gptkbp:reproduction caution advised
gptkbp:requires prescription only
gptkbp:research_focus patient quality of life
cost-effectiveness
long-term effects
comparative effectiveness
gptkbp:safety_features generally well tolerated
gptkbp:side_effect dry eyes
eye irritation
hyperemia
periorbital skin pigmentation
changes in eyelash growth
eyelash darkening
iris pigmentation
gptkbp:type_of_care important for efficacy